Cellectis S.A. (EPA:ALCLS)
France · Delayed Price · Currency is EUR 3.250
-0.015 (-0.46%)
At close: Jan 30, 2026
Cellectis Market Cap
Cellectis has a market cap or net worth of €235.06 million as of January 30, 2026. Its market cap has increased by 116.91% in one year.
Market Cap
235.06M
Enterprise Value
266.26M
Revenue
70.36M
Ranking
n/a
PE Ratio
n/a
Stock Price
€3.25
Market Cap Chart
Since February 7, 2007, Cellectis's market cap has increased from 100.59M to 235.06M, an increase of 133.67%. That is a compound annual growth rate of 4.57%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 30, 2026 | 235.06M | -22.53% |
| Dec 31, 2025 | 303.40M | 158.68% |
| Dec 31, 2024 | 117.29M | -40.86% |
| Dec 29, 2023 | 198.32M | 118.98% |
| Dec 30, 2022 | 90.57M | -73.23% |
| Dec 31, 2021 | 338.35M | -67.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| MedinCell | 764.01M |
| Valneva SE | 674.24M |
| Genfit | 281.34M |
| Transgene | 251.37M |
| Innate Pharma | 145.61M |
| ABIONYX Pharma | 135.11M |
| MaaT Pharma | 123.69M |
| Adocia | 117.95M |